Search PubMed⌕ Search

Biomedical subjects

A Lewis

Publications and source records attributed to A Lewis.

304 records · Page 17Linked to original sources
PubMedDate not supplied

Translating pressure ulcer guidelines into practice: it's harder than it sounds.

OBJECTIVE: To determine the cost-effectiveness of a guideline-based pressure ulcer prevention protocol over time. DESIGN: Retrospective and prospective quasi-experimental longitudinal design. Costs are presented from the long-term-care facility perspective. Data collection occurred for 3 periods: the first 6 months of 1994 (prior to protocol implementation), the first 6 months of 1995 (immediately following implementation) and the first 6 months of 1997 (2 years following implementation). SETTING: 77-bed long-term-care facility PATIENTS/PARTICIPANTS: Subjects were ulcer-free facility residents at the start of each data collection period. There were 69 subjects in the 1994 sample, 63 in the 1995 sample, and 71 in the 1997 sample. INTERVENTIONS: A guideline-based pressure ulcer prevention protocol was implemented during the last 3 months of 1994. The protocol consisted of specific policies for pressure ulcer prevention and treatment, intensive staff education on pressure ulcer care, and monitoring with regular performance feedback to staff. MEASUREMENTS AND MAIN RESULTS: Time to ulcer development varied among the 3 groups (log rank = 8.81, P = .01), with longer time to ulcer development in 1995 compared with 1994; no difference was seen between 1997 and 1994. The time for ulcers to heal decreased over the 3 years (log rank = 9.49, P <.01), with ulcer healing time being shorter in 1995 and 1997 compared with 1994. Total costs were unchanged during the 3 years (F = 0.2, P =.81). Costs of treatment declined significantly from 1994 to 1995 and 1997 (F = 5.5, P <.01) and costs of prevention increased significantly from 1994 to 1995 and 1997(F = 15, P <.01). From 1994 to 1997, the cost for 1 day of ulcer-free life was $3.50. CONCLUSIONS: Implementation of a pressure ulcer prevention protocol showed mixed results. Initial reductions in pressure ulcer incidence were lost over time. Clinical results of ulcer treatment, however, improved and treatment costs fell during the 3 years. Implementation of preventive programs poses a major leadership challenge.

Aged↗
PubMedDate not supplied

Regulation of recombinant human brain tandem P domain K+ channels by hypoxia: a role for O2 in the control of neuronal excitability?

The tandem P domain potassium channels, TREK1 and TASK1, are expressed throughout the brain but expression patterns do not significantly overlap. Since normal pO2 in central nervous tissue is as low as 20 mmHg and can decrease even further in ischemic disease, it is important that the behaviour of human brain ion channels is studied under conditions of acute and chronic hypoxia. This is especially true for brain-expressed tandem P-domain channels principally because they are important contributors to neuronal resting membrane potential and excitability. Here, we discuss some recent data derived from two recombinant tandem P-domain potassium channels, hTREK1 and hTASK1. Hypoxia represents a potent inhibitory influence on both channel types and occludes the activation by arachidonic acid, intracellular acidosis and membrane deformation of TREK1. This casts doubt on the idea that TREK1 activation during brain ischemia might facilitate neuroprotection via hyperpolarising neurons in which it is expressed. Interestingly, hypoxia is unable to regulate alkalotic inhibition of TREK1 suggesting that this channel may be more intimately involved in control of excitability during physiological or pathological alkalosis.

Arachidonic Acid↗
PubMedDate not supplied

Lack of pharmacokinetic interaction between gemifloxacin and digoxin in healthy elderly volunteers.

Gemifloxacin is a novel fluoroquinolone with a broad spectrum of antibacterial activity. The objective of this double-blind, randomized, placebo-controlled, 2-way crossover study was to demonstrate the lack of a pharmacokinetic interaction between gemifloxacin and digoxin. During two 14-day treatment periods, healthy elderly volunteers received digoxin (0.25 mg, once daily) co-administered on days 8-14 with either gemifloxacin (320 mg, p.o., once daily) or placebo. On day 14 of each period, blood samples and urine were collected for 24 h post dose and analysed for digoxin levels by radioimmunoassay. Steady-state digoxin pharmacokinetics were not affected by multiple dosing with gemifloxacin. There was no significant difference in digoxin values for the area under the plasma concentration-time curve over the dosing interval 0-24 h (AUC((0-24))) or the trough plasma concentration (C24) after co-administration with either gemifloxacin or placebo. Geometric means for AUC((0-24)) and C24 were 18.1 and 17.8 ng x h/ml and 0.597 and 0.566 ng/ml, respectively. The point estimates (90% confidence intervals) for AUC((0-24)) and C24 (digoxin + gemifloxacin):(digoxin + placebo) were 1.01 (0.93, 1.10) and 1.05 (0.95, 1.16), respectively, entirely within the equivalence range (0.80, 1.25). There were no marked differences between co-administration regimens for maximum observed plasma concentration (C(max)) or renal clearance values. Gemifloxacin was well tolerated during co-administration with digoxin, and the incidence of adverse events was similar to that seen with placebo. There were no clinically relevant changes in vital signs, electrocardiogram readings or laboratory parameters. In conclusion, this study demonstrates that gemifloxacin may be co-administered with digoxin without the need for digoxin dose adjustment.

Aged↗
PubMedDate not supplied

Effect of omeprazole on the pharmacokinetics of oral gemifloxacin in healthy volunteers.

This randomized, double-blind, 2-way crossover study investigated the effect of omeprazole on the pharmacokinetics of gemifloxacin, a novel fluoroquinolone. Thirteen healthy male volunteers received a 320 mg oral dose of gemifloxacin after 4 days of dosing with either omeprazole (40 mg once daily) or matching placebo. Blood was sampled for 48 h after dosing for determination of pharmacokinetic parameters. The mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-infinity)) and maximum plasma concentration (C(max)) for gemifloxacin were increased by, on average, 10% (90% confidence interval [CI], 0.89, 1.36) and 11% (90% CI, 0.87, 1.43), respectively, when gemifloxacin was given after omeprazole compared with after placebo. Neither the time to C(max) (T(max)) nor the half-life of gemifloxacin appeared to be affected by administration of omeprazole. There were no clinically relevant changes in adverse events, vital signs or the results of laboratory investigations after co-administration of omeprazole compared with placebo. In view of the modest increase in systemic exposure and the likely maximal increases indicated by the CIs, the effect of omeprazole on gemifloxacin pharmacokinetics is not considered to be clinically significant. Gemifloxacin and omeprazole can therefore be co-administered with no requirement for a dose adjustment.

Administration, Oral↗
PubMedDate not supplied

Effect of Maalox on the bioavailability of oral gemifloxacin in healthy volunteers.

This open, randomized, 4-way crossover study investigated the effect of the antacid Maalox on the bioavailability of gemifloxacin, a novel fluoroquinolone antimicrobial. Sixteen healthy male volunteers received gemifloxacin, 320 mg p.o., alone, 3 h after Maalox administration, or 10 min or 2 h before Maalox administration. Blood was sampled for 48 h after dosing to determine pharmacokinetic parameters. Estimates for the differences between regimens and 95% confidence intervals were calculated using the t-test for paired data. The administration of gemifloxacin 10 min before Maalox resulted in an average 85% reduction in the area under the plasma concentration-time curve from time zero extrapolated to infinity (AUC(0-infinity)), whereas administration 3 h after Maalox produced a decrease in AUC(0-infinity), 15% of which was not considered to be clinically significant. The administration of gemifloxacin 2 h before Maalox had no notable effect on the gemifloxacin AUC(0-infinity) (average increase of 3%). Similar results were seen for the maximum gemifloxacin plasma concentration (C(max)). Neither the time to C(max) nor the half-life of gemifloxacin were notably altered by the administration of Maalox at any time relative to gemifloxacin dosing. There were no clinically important adverse experiences or changes in clinical laboratory parameters during this study. The findings of this study support the dosing recommendation that gemifloxacin can be administered either 2 h or more prior to, or 3 h or more after, the administration of Maalox.

Administration, Oral↗
PubMedDate not supplied

Reinvigorating stalled CQI efforts through physician involvement.

Continuous quality improvement (CQI), loosely synonymous with total quality management (TQM), was designed for the comparatively simple world of industry. Now that the gurus of CQI have attempted--originally with full support of the Joint Commission on Accreditation of Healthcare Organizations (JCAHO)--to apply the industrial CQI model to hospitals, they've noticed something: The model doesn't work, and hospital CQI programs are faltering enough to persuade the Joint Commission to scale back its CQI accreditation requirements. One major shortcoming behind the performance to date of CQI in hospitals: Physicians don't fit into the industrial model of CQI. Physicians are too important, and too many programs are stalled, to continue to implement CQI as though physicians don't exist. The techniques described here should help to reinvigorate faltering programs, giving hospital management a chance to "do it right the second time."

Hospital Administration↗
PubMedDate not supplied

Health plan ordered to pay high penalty.

Litigation on the basis of wrongful denial of medical benefits can literally cripple a health plan. If it can happen at Health Net, it can happen to almost any plan.

Bone Marrow Transplantation↗
PubMedDate not supplied

Rescue remedy.

Explore the source record for details and available documents.

Community Health Nursing↗
PubMedDate not supplied

Team or primary nursing care?

This study was undertaken to help nursing administration make policy decisions regarding the initiation of primary care nursing and the need to hire RNS. The work involved an experimental design using 11 units in a 350-bed facility. The results show no significant differences between the two methods regarding quality, cost, job satisfaction, patient satisfaction, or patient education. Moreover, the 16-hour model produces more stress and more sick leave days than team nursing. It is also apparent that apart from salaries, the cost of nursing care is a function of the diagnoses of the patients in the hospital, which may account for some of the inconsistencies found in the literature. If the ratio of RN to non-RN staff had been increased, the results might have been different; however, Giovanetti's comparison study of primary and team nursing, which considered the same factors but used a 70-percent-RN staff, produced similar results. It appears that individual RN's dedication and preparation for patient care may be more important than the method used to organize that care. Research to determine how to select the most appropriate nurse for a specific role would be a more productive approach to assist policy determination in the future.

Costs and Cost Analysis↗
PubMedDate not supplied

Cost-effectiveness of an intensive pressure ulcer prevention protocol in long-term care.

Conducted in a 77-bed long-term-care facility, this study compared the costs of implementing an intensive pressure ulcer prevention protocol plus the calculated costs of treatment before and after implementing the protocol. A total of 69 patients comprised the preprotocol sample; 16 of them developed 26 ulcers. The postprotocol sample consisted of 63 patient, 3 of whom developed 5 ulcers. The 6-month pressure ulcer incidence was 23% in the preprotocol sample and 5% in the postprotocol sample. Mean cost for prevention and treatment of pressure ulcers was $113 +/- $345 per subject for the preprotocol sample and $100 +/- $157 per subject for the postprotocol sample (t = 0.27, df = 130, p = .79). Mean time to ulcer development was 146 +/- 61 days for the preprotocol subjects and 158 +/- 53 days for the postprotocol subjects (log rank = 8.63, p = .003 Implementation of a protocol that emphasized pressure ulcer prevention significantly reduced the incidence of pressure ulcers and cost per day of ulcer-free life.

Aged↗